Sign In

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.


Scil Technology – a New German Biopharmaceutical Company – is Launched by the Scil Group
Irina Staatz-Granzer is Named Managing Director

Scil Technology will develop innovative products for bone and cartilage regeneration in dentistry and orthopaedics, combining synthetic, resorbable scaffolds with bone and cartilage specific proprietary growth factors. The Company has a proprietary protein coating technology that ensures a homogenous and stable coating of growth factor on various matrices and implants, allowing for controlled release of the growth factors in vivo.
Dr Irina Staatz-Granzer, Managing Director of Scil Technology, commented:
“I am delighted to be taking on this challenging role within Scil Technology, a new company at the forefront of pioneering regenerative dental and orthopaedic biomaterials. With its experienced development team, Scil Technology starts its life well placed to become one of the leading regenerative companies in the world.”
Dr Staatz-Granzer has more than 15 years' industrial experience in the pharmaceutical industry. She joined the Scil Group in 2002 as Vice President of Business Development of Scil Biomedicals. Before joining Scil she served as Director of Business Development at Knoll later Abbott. Prior to that, she held leading management positions in analytical development, international marketing and business development at Hermal Kurt Herrmann, a former 100% subsidiary of Merck KGaA, later Boots Healthcare International.
Scil Technology is a subsidiary of Bionet Holding GmbH and is the major shareholder of Scil Proteins GmbH. Scil Technology is located in Martinsried/Munich.

– ends –

About Scil Technology GmbH
Scil Technology is a private biopharmaceutical development company focused on dental and orthopaedic tissue regeneration with a particular emphasis on bone and cartilage repair. The Company’s lead therapeutic candidates are based on recombinant, highly specific human growth factors. These are combined with biodegradable biomaterials to generate local application forms. Scil Technology’s pipeline for dentistry includes products that are targeted at periodontal disease, dental implantology and maxillofacial surgery. Orthopaedic products are developed for spinal fusion, traumatic lesions of bone and cartilage tissue and osteoarthritis. Scil Technology has emerged from the Scil Group and is located in the biotechnology cluster in Martinsried, Germany.
For more information please visit:

Publisher Contact Information:

Scil Technology GmbH
+49 (0)89 85651824

Company profile of Scil Technology GmbH
Past press releases of Scil Technology GmbH.


Tech investments
From our Online Data Service
VC-backed companies
From our Radar

Recent Deals

Nov 25€24.0MInternet commerce
Feb 14€19.0MBiopharmaceuticals
Feb 14N/AInternet services
Feb 14€4.6MBusiness applications
Feb 13€13.0MBiopharmaceuticals
Feb 13€25.0MMedical devices
Feb 13€15.0MBusiness applications

For information on Europe's most extensive database on technology funding click here!


Press Releases

May 28
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
nethone raised over $1 million from innovation nest

Jan 29
yumpingo raises $10m to transform guest experiences in restaurants

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.